VigenCell, a company specializing in immune cell therapy, is moving toward early commercialization after presenting significant results in Phase 2 ...
Extranodal natural killer (NK)/T-cell lymphoma, nasal type, is a rare peripheral T-cell lymphoma associated with Epstein-Barr virus. It most often presents as limited-stage disease in patients of East ...
A 73-year-old male with a history of relapsed/refractory NK T-cell lymphoma, s/p chemo and immune checkpoint inhibitors therapy. The patient now presents with new onset nephrotic syndrome and acute ...
Phase II Study of Neoadjuvant Chemotherapy and Radiation Therapy in the Management of High-Risk, High-Grade, Soft Tissue Sarcomas of the Extremities and Body Wall: Radiation Therapy Oncology Group ...
Granulocyte colony-stimulating factor to be started on day 6. Cycles to be repeated every 28 days. SMILE: Dexamethasone, methotrexate, ifosfamide, L-asparaginase and etoposide. Stage I/II ...
SOUTH SAN FRANCISCO, Calif., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company, today announced that final data from its Phase 1 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback